87th European Atherosclerosis Society Congress 2019
FIND-FH: Understanding FH prevalence in South Africa
Familial hypercholesterolaemia (FH, inherited high cholesterol) is one of the commonest inherited diseases in the world with an estimated frequency of 1:200 to 1:250 for Caucasian populations1. In South Africa, the prevalence in certain population groups such as the Afrikaner, Jewish and south-Asian Indians is…
read more »
More data on real-world use of PCSK9 inhibitors
From Spain Data from Spain shows that the PCSK9 inhibitor evolocumab is mainly prescribed to patients with familial hypercholesterolaemia (FH, inherited high cholesterol and/or clinical atherosclerotic disease, according to this report.)1 In Spain, hypercholesterolaemia is mainly managed at internal medical units, focusing on patients with…
read more »
News from the ORION programme with inclisiran: ORION-2, ORION-3
Inclisiran (an siRNA therapeutic targeting PCSK9) showed promise in patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the proof-of-concept ORION-2 trial.1 Results were reported at the first late breaking session of the EAS Congress in Maastricht by lead investigator, Professor Derick Raal (University…
read more »
Phase 2 data with novel adnectin PCSK9 inhibitor LIB003
EAS Congress also reported news for LIB003, a recombinant fusion protein therapeutic agent consisting of a PCSK9-binding domain (adnectin) and human serum albumin. In high risk patients with hypercholesterolaemia, LIB003 reduced LDL cholesterol by more than 70% in this 12-week trial.1 Compared with the PCSK9…
read more »
Screening for FH paramount to avoid early loss of life
Analysis of more than 1.7 million patient records in the UK Clinical Practice Research Datalink database, showed that many patients with likely familial hypercholesterolaemia (FH, inherited high cholesterol) are not diagnosed. This is important as these individuals are twice as likely to die prematurely –…
read more »
